IL182279A0 - Angiopoietin-2-specific binding agents - Google Patents

Angiopoietin-2-specific binding agents

Info

Publication number
IL182279A0
IL182279A0 IL182279A IL18227907A IL182279A0 IL 182279 A0 IL182279 A0 IL 182279A0 IL 182279 A IL182279 A IL 182279A IL 18227907 A IL18227907 A IL 18227907A IL 182279 A0 IL182279 A0 IL 182279A0
Authority
IL
Israel
Prior art keywords
angiopoietin
specific binding
binding agents
agents
specific
Prior art date
Application number
IL182279A
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL182279A0 publication Critical patent/IL182279A0/en

Links

IL182279A 2004-10-19 2007-03-28 Angiopoietin-2-specific binding agents IL182279A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents
PCT/US2005/037911 WO2006045049A1 (fr) 2004-10-19 2005-10-19 Agents de liaison specifiques de l'angiopoietine-2

Publications (1)

Publication Number Publication Date
IL182279A0 true IL182279A0 (en) 2007-07-24

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
IL182279A IL182279A0 (en) 2004-10-19 2007-03-28 Angiopoietin-2-specific binding agents

Country Status (10)

Country Link
JP (2) JP2008520188A (fr)
CN (1) CN101495513B (fr)
BR (1) BRPI0518209A (fr)
EA (1) EA011866B1 (fr)
IL (1) IL182279A0 (fr)
MA (1) MA29015B1 (fr)
MX (1) MX2007004247A (fr)
RU (2) RU2404992C2 (fr)
SG (1) SG156668A1 (fr)
ZA (1) ZA200704020B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
PT2760471T (pt) * 2011-09-30 2017-03-22 Dana Farber Cancer Inst Inc Péptidos terapêuticos
NZ627859A (en) * 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
US9534007B2 (en) 2012-12-21 2017-01-03 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
CN105264380B (zh) * 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
CA2957005C (fr) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. Derive de quinoline de purete elevee et son procede de fabrication
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (fr) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
CN106512006A (zh) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Angpt2分泌抑制剂在制备用于治疗血管瘤的药物中的应用
CN106075448A (zh) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 Angpt2抑制剂在制备用于治疗血管瘤的药物中的应用
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
CN109096368B (zh) * 2018-09-30 2021-07-20 华南理工大学 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用
CN113728004A (zh) * 2019-02-25 2021-11-30 药物抗体公司 抗Ang2抗体及其用途
CN112126671B (zh) * 2020-08-18 2021-08-31 中山大学附属第五医院 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
CN116265487B (zh) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368670C (fr) * 1999-03-26 2012-06-05 Chitra Suri Modulation de la permeabilite vasculaire au moyen d'activateurs de recepteurs tie2
IL145941A (en) * 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
HUP0302779A3 (en) * 2000-06-23 2005-12-28 Schering Ag Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
EP1458367B2 (fr) * 2001-10-12 2021-01-27 Aquestive Therapeutics, Inc. Couches minces uniformes servant a dissoudre rapidement une forme galenique incorporant des compositions de masquage de gout
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2

Also Published As

Publication number Publication date
JP2011207882A (ja) 2011-10-20
ZA200704020B (en) 2008-06-25
CN101495513B (zh) 2014-08-06
EA200700876A1 (ru) 2007-10-26
RU2007118670A (ru) 2008-12-27
CN101495513A (zh) 2009-07-29
RU2404992C2 (ru) 2010-11-27
BRPI0518209A (pt) 2008-11-04
SG156668A1 (en) 2009-11-26
JP2008520188A (ja) 2008-06-19
EA011866B1 (ru) 2009-06-30
MA29015B1 (fr) 2007-11-01
RU2010132956A (ru) 2012-02-10
MX2007004247A (es) 2007-06-12

Similar Documents

Publication Publication Date Title
GB0404187D0 (en) Binding agents
GB0521991D0 (en) Siglec-9 binding agents
IL179661A0 (en) Il-13 binding agents
DE602005025924D1 (en) Royl-coa-desaturase
DE602005020252D1 (en) Röhrenförmige prothese
AP2006003810A0 (en) 4-Phenylamino-quinazolin-6-yl-amides
DE602004014986D1 (en) Terminal-box
EG23651A (en) Culturama
DE602005010905D1 (en) Roboterhandvorrichtung
DE602005007474D1 (en) Substituierte morpholin- und thiomorpholinderivate
DE602005011286D1 (en) Pyrazolopyridinderivate
DE502005007040D1 (en) Laryngoskop
DE502005007456D1 (en) Nanoemulsionen
DE602005008719D1 (en) Notinformationsschild
DE602005026795D1 (en) Polythiourethan
DE502004004685D1 (en) Giessmaschine
EP1710096A4 (fr) Dispositif de reliure
DE602005010119D1 (en) Roboterhandvorrichtung
DE602005010440D1 (en) Lymerdispersionen
DE502005009795D1 (en) Modulares gelenkprothesensystem
DE602005025096D1 (en) Rotationsdämpfer
DE602005003029D1 (en) Polyaminoamidmonoepoxyaddukte
GB0410627D0 (en) Specific binding members
DE502005010653D1 (en) Eiten
DE502004004917D1 (en) Multiaxialkomplex